MBT FAST试验:基于MALDI-TOF MS的6小时快速药敏检测
本研究评估了基于MALDI-TOF MS的MBT FAST试验,采用直接靶板微滴生长法对243株肠杆菌科菌进行19种抗生素的药敏试验,孵育6小时后与微量肉汤稀释法比较。总体基本一致率为96.0%,表明该研究用试验可在6小时内提供可靠药敏结果,显著缩短周转时间。
要点
- MBT FAST试验可在6小时内完成肠杆菌科菌的药敏检测。
- 与微量肉汤稀释法相比,总体基本一致率达96.0%。
- 该技术基于广泛使用的MALDI-TOF MS平台,易于整合到临床流程。
核心结论
- MBT FAST研究用试验可在6小时内提供可靠的肠杆菌科菌药敏结果,与微量肉汤稀释法高度一致。
研究设计与样本
- 评估基于MALDI-TOF MS的MBT FAST试验,采用直接靶板微滴生长法进行表型药敏试验,共测试243株肠杆菌科分离株,针对19种抗生素,以微量肉汤稀释法为参考方法。
主要发现
- 所有分离株均获得有效生长对照;总体基本一致率(EA)为96.0%。
- 各抗生素EA范围从美罗培南87.2%到左氧氟沙星97.9%等,具体数值见原文。
关键数值与推荐
- 基本一致率(EA)定义为MIC在标准方法±1个倍比稀释度内。
- 各抗生素EA:阿莫西林/克拉维酸96.3%、阿米卡星97.5%、氨曲南95.5%、头孢他啶/阿维巴坦95.5%、头孢他啶94.6%、头孢吡肟92.2%、环丙沙星91.8%、黏菌素92.2%、头孢曲松95.5%、头孢噻肟94.2%、庆大霉素95.5%、亚胺培南91.8%、左氧氟沙星97.9%、美罗培南87.2%、美罗培南/伐硼巴坦94.2%、哌拉西林/他唑巴坦90.9%、甲氧苄啶/磺胺甲噁唑90.9%、替莫西林93.3%、妥布霉素97.5%。
临床怎么用
- 该研究用试验可在6小时内提供药敏结果,有助于早期指导治疗和降阶梯治疗。
- 基于广泛使用的MALDI-TOF MS平台,便于整合到微生物实验室常规工作流程。
局限性
- 该试验为研究用途,尚未获得临床诊断许可。
- 研究仅纳入肠杆菌科菌,其他菌种需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The rise of multidrug-resistant microorganisms highlights the need for rapid antimicrobial susceptibility testing (AST) to guide early and effective therapy. This study evaluated a novel MALDI-TOF MS-based assay (MBT FAST, Bruker, Germany), which employs the direct-on-target microdroplet growth assay (DOT-MGA) for phenotypic AST. A total of 243 Enterobacteriaceae isolates representing diverse species and resistance patterns were tested against a broad panel of antibiotics. Each isolate was incubated in 6-µL microdroplets of cation-adjusted Mueller-Hinton broth, with and without antibiotics at two-fold serial dilutions, at 35°C for 6 h inside a humidity-controlled chamber (MBT FAST Shuttle, Bruker). Broth was removed using a prototype device (MBT FAST Stamp, Bruker), and MALDI-TOF MS measurements were performed with the MALDI Biotyper Sirius system (Bruker). Results were compared with broth microdilution as the standard for determining minimum inhibitory concentrations (MIC). Valid growth control was achieved for 100% of isolates. Essential agreement (EA), defined as MICs within ±1 two-fold dilution step of the standard method, was as follows: amoxicillin/clavulanic acid 96.3%, amikacin 97.5%, aztreonam 95.5%, ceftazidime/avibactam 95.5%, ceftazidime 94.6%, cefepime 92.2%, ciprofloxacin 91.8%, colistin 92.2%, ceftriaxone 95.5%, cefotaxime 94.2%, gentamicin 95.5%, imipenem 91.8%, levofloxacin 97.9%, meropenem 87.2%, meropenem/vaborbactam 94.2%, piperacillin/tazobactam 90.9%, trimethoprim/sulfamethoxazole 90.9%, temocillin 93.3%, and tobramycin 97.5%. The overall EA across all antimicrobials tested reached 96.0%. The research-use-only MBT FAST assay provides reliable AST within 6 h, substantially reducing turnaround time. Building on technology widely implemented in diagnostic laboratories, this approach holds promise for integration into microbiology practice. IMPORTANCE: Standard antimicrobial susceptibility testing requires prolonged incubation, delaying targeted treatment and de-escalation. This study evaluated MBT FAST, a MALDI-TOF MS-based assay that measures bacterial growth directly on the MALDI target plate in the presence of antibiotics. In a diverse collection of Enterobacteriaceae tested against a panel of 19 antibiotics, the assay provided reliable minimum inhibitory concentration results after 6 h and showed high agreement with standard broth microdilution. Because MALDI-TOF MS instruments are widely used in clinical microbiology laboratories, this approach could make rapid phenotypic susceptibility testing easier to integrate into routine workflows.
引用
- Idelevich EA, Alpers K, Buhl M, et al. Rapid MALDI-TOF MS antimicrobial susceptibility testing with the MBT FAST assay. J Clin Microbiol. 2026. PMID: 42626954. doi:10.1128/jcm.00259-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。